Susan Burgin, D.T.M.&H., M.B.,B.Ch.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dermatology | 29 | 2022 | 885 | 8.240 |
Why?
|
| Teaching | 14 | 2019 | 1176 | 4.500 |
Why?
|
| Learning | 12 | 2020 | 1727 | 2.610 |
Why?
|
| Teaching Rounds | 3 | 2016 | 266 | 1.170 |
Why?
|
| Drug Eruptions | 4 | 2021 | 304 | 1.140 |
Why?
|
| Skin Diseases | 6 | 2017 | 1073 | 1.110 |
Why?
|
| Skin | 9 | 2021 | 4393 | 1.060 |
Why?
|
| Education, Medical | 4 | 2018 | 1724 | 0.870 |
Why?
|
| Exanthema | 4 | 2017 | 506 | 0.850 |
Why?
|
| Problem-Based Learning | 4 | 2018 | 362 | 0.840 |
Why?
|
| Educational Measurement | 2 | 2018 | 1221 | 0.770 |
Why?
|
| Dermatitis, Contact | 1 | 2021 | 129 | 0.740 |
Why?
|
| Psychological Theory | 2 | 2018 | 168 | 0.710 |
Why?
|
| Education, Medical, Continuing | 2 | 2016 | 844 | 0.700 |
Why?
|
| Art | 1 | 2020 | 65 | 0.680 |
Why?
|
| Faculty, Medical | 2 | 2017 | 1187 | 0.650 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2018 | 1022 | 0.650 |
Why?
|
| Vulva | 1 | 2018 | 87 | 0.640 |
Why?
|
| Eczema | 1 | 2021 | 234 | 0.640 |
Why?
|
| Models, Educational | 2 | 2018 | 384 | 0.630 |
Why?
|
| Preceptorship | 1 | 2018 | 61 | 0.620 |
Why?
|
| Graft vs Host Reaction | 1 | 2017 | 104 | 0.610 |
Why?
|
| Acyclovir | 2 | 2016 | 274 | 0.600 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 2017 | 46 | 0.600 |
Why?
|
| Internship and Residency | 7 | 2019 | 5858 | 0.590 |
Why?
|
| Mohs Surgery | 1 | 2018 | 207 | 0.550 |
Why?
|
| Folliculitis | 1 | 2016 | 28 | 0.540 |
Why?
|
| Vulvar Neoplasms | 1 | 2018 | 273 | 0.540 |
Why?
|
| Fibroma | 1 | 2017 | 216 | 0.520 |
Why?
|
| Calciphylaxis | 1 | 2017 | 126 | 0.520 |
Why?
|
| Still's Disease, Adult-Onset | 1 | 2014 | 19 | 0.510 |
Why?
|
| Malignant Atrophic Papulosis | 1 | 2014 | 7 | 0.500 |
Why?
|
| Herpesvirus 3, Human | 1 | 2016 | 208 | 0.490 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2015 | 72 | 0.490 |
Why?
|
| Education | 1 | 2017 | 543 | 0.470 |
Why?
|
| Valine | 1 | 2016 | 411 | 0.470 |
Why?
|
| Foot Diseases | 1 | 2015 | 144 | 0.470 |
Why?
|
| Bronchiectasis | 1 | 2015 | 130 | 0.460 |
Why?
|
| Onycholysis | 1 | 2013 | 3 | 0.460 |
Why?
|
| Peer Group | 1 | 2018 | 650 | 0.450 |
Why?
|
| Motivation | 3 | 2018 | 1990 | 0.450 |
Why?
|
| Epidermolysis Bullosa Acquisita | 1 | 2013 | 14 | 0.450 |
Why?
|
| Hospitals, Teaching | 1 | 2018 | 1183 | 0.450 |
Why?
|
| Herpes Zoster | 1 | 2016 | 264 | 0.450 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2018 | 557 | 0.440 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 948 | 0.420 |
Why?
|
| Sarcoma, Kaposi | 1 | 2015 | 379 | 0.410 |
Why?
|
| Culture | 1 | 2016 | 636 | 0.400 |
Why?
|
| Ambulatory Care Facilities | 1 | 2018 | 936 | 0.400 |
Why?
|
| Skin Neoplasms | 3 | 2018 | 5751 | 0.400 |
Why?
|
| Dermatomyositis | 1 | 2014 | 225 | 0.400 |
Why?
|
| Workload | 1 | 2017 | 857 | 0.400 |
Why?
|
| Pemphigus | 1 | 2012 | 112 | 0.380 |
Why?
|
| Physical Examination | 1 | 2016 | 1237 | 0.370 |
Why?
|
| Ambulatory Care | 2 | 2018 | 2738 | 0.360 |
Why?
|
| Cooperative Behavior | 1 | 2017 | 1508 | 0.360 |
Why?
|
| Chromoblastomycosis | 1 | 2009 | 1 | 0.360 |
Why?
|
| Buttocks | 1 | 2009 | 114 | 0.330 |
Why?
|
| Patients | 1 | 2015 | 904 | 0.330 |
Why?
|
| Ascomycota | 1 | 2009 | 85 | 0.330 |
Why?
|
| Education, Medical, Graduate | 2 | 2018 | 2322 | 0.320 |
Why?
|
| Students | 2 | 2022 | 1668 | 0.320 |
Why?
|
| Herpes Simplex | 1 | 2012 | 473 | 0.320 |
Why?
|
| Humans | 58 | 2022 | 752741 | 0.320 |
Why?
|
| Attitude to Health | 1 | 2016 | 2058 | 0.300 |
Why?
|
| Clinical Competence | 2 | 2019 | 4729 | 0.290 |
Why?
|
| Liver Cirrhosis | 1 | 2017 | 1902 | 0.280 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2016 | 1185 | 0.280 |
Why?
|
| Emotions | 1 | 2018 | 2684 | 0.270 |
Why?
|
| Granuloma Annulare | 1 | 2005 | 28 | 0.260 |
Why?
|
| Cytomegalovirus Infections | 1 | 2012 | 817 | 0.260 |
Why?
|
| Rickettsiaceae Infections | 1 | 2004 | 2 | 0.260 |
Why?
|
| Referral and Consultation | 1 | 2018 | 3573 | 0.260 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2017 | 4562 | 0.250 |
Why?
|
| Mucous Membrane | 1 | 2008 | 673 | 0.240 |
Why?
|
| Telemedicine | 1 | 2021 | 2990 | 0.240 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 3433 | 0.240 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2003 | 43 | 0.230 |
Why?
|
| Quality Improvement | 1 | 2018 | 3808 | 0.220 |
Why?
|
| Adenoma, Sweat Gland | 1 | 2002 | 18 | 0.210 |
Why?
|
| History, 19th Century | 2 | 2015 | 722 | 0.210 |
Why?
|
| Eccrine Glands | 1 | 2002 | 49 | 0.210 |
Why?
|
| History, 21st Century | 2 | 2020 | 1552 | 0.200 |
Why?
|
| Water Loss, Insensible | 1 | 2021 | 12 | 0.200 |
Why?
|
| Emollients | 1 | 2021 | 34 | 0.190 |
Why?
|
| Erythema | 2 | 2017 | 261 | 0.190 |
Why?
|
| Students, Medical | 3 | 2018 | 1887 | 0.190 |
Why?
|
| Histamine Antagonists | 1 | 2021 | 94 | 0.190 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2002 | 117 | 0.180 |
Why?
|
| History, 20th Century | 2 | 2020 | 2766 | 0.180 |
Why?
|
| Antiviral Agents | 3 | 2021 | 3012 | 0.180 |
Why?
|
| Crohn Disease | 1 | 2013 | 2321 | 0.180 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 5469 | 0.170 |
Why?
|
| Humanities | 1 | 2020 | 53 | 0.170 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 4929 | 0.160 |
Why?
|
| Administration, Cutaneous | 1 | 2021 | 712 | 0.160 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2002 | 603 | 0.160 |
Why?
|
| Antigens, CD | 1 | 2008 | 4028 | 0.150 |
Why?
|
| Internet | 2 | 2021 | 3074 | 0.150 |
Why?
|
| Thiosulfates | 1 | 2017 | 52 | 0.150 |
Why?
|
| Group Processes | 1 | 2018 | 226 | 0.140 |
Why?
|
| Thinking | 1 | 2020 | 318 | 0.140 |
Why?
|
| Observation | 1 | 2018 | 315 | 0.140 |
Why?
|
| Angiomatosis, Bacillary | 1 | 1996 | 4 | 0.140 |
Why?
|
| Urban Population | 1 | 2004 | 2031 | 0.140 |
Why?
|
| Leg Ulcer | 1 | 2016 | 69 | 0.130 |
Why?
|
| Chelating Agents | 1 | 2017 | 378 | 0.130 |
Why?
|
| Personal Autonomy | 1 | 2018 | 300 | 0.130 |
Why?
|
| Videoconferencing | 1 | 2017 | 200 | 0.130 |
Why?
|
| Biopsy | 2 | 2018 | 6771 | 0.130 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2016 | 78 | 0.130 |
Why?
|
| Physician Executives | 1 | 2015 | 128 | 0.120 |
Why?
|
| Feedback | 1 | 2018 | 792 | 0.120 |
Why?
|
| Thigh | 1 | 2016 | 246 | 0.120 |
Why?
|
| History, 18th Century | 1 | 2015 | 214 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 2 | 2008 | 9300 | 0.120 |
Why?
|
| Sweating | 1 | 2014 | 124 | 0.120 |
Why?
|
| Stomach Ulcer | 1 | 2014 | 127 | 0.120 |
Why?
|
| Self Efficacy | 1 | 2018 | 623 | 0.120 |
Why?
|
| Histiocytosis | 1 | 2013 | 40 | 0.120 |
Why?
|
| Diagnosis, Differential | 3 | 2017 | 13042 | 0.110 |
Why?
|
| Esophageal Diseases | 1 | 2014 | 168 | 0.110 |
Why?
|
| Administration, Oral | 1 | 2021 | 3941 | 0.110 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2015 | 289 | 0.110 |
Why?
|
| Comprehension | 1 | 2018 | 617 | 0.110 |
Why?
|
| Ulcer | 1 | 2014 | 210 | 0.110 |
Why?
|
| Male | 17 | 2018 | 354311 | 0.110 |
Why?
|
| Educational Status | 1 | 2020 | 2573 | 0.110 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 2125 | 0.110 |
Why?
|
| Patient Participation | 1 | 2021 | 1464 | 0.100 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1996 | 654 | 0.100 |
Why?
|
| Lymphatic Diseases | 1 | 2013 | 323 | 0.100 |
Why?
|
| Biological Products | 1 | 2021 | 881 | 0.100 |
Why?
|
| Awareness | 1 | 2016 | 643 | 0.100 |
Why?
|
| Glucocorticoids | 1 | 2021 | 2129 | 0.100 |
Why?
|
| Ganciclovir | 1 | 2012 | 257 | 0.100 |
Why?
|
| Muscle Weakness | 1 | 2014 | 415 | 0.100 |
Why?
|
| Radiography, Thoracic | 1 | 2017 | 1279 | 0.100 |
Why?
|
| Program Evaluation | 1 | 2019 | 2502 | 0.100 |
Why?
|
| Adult | 13 | 2016 | 216658 | 0.090 |
Why?
|
| Prednisolone | 1 | 2012 | 333 | 0.090 |
Why?
|
| Attitude | 1 | 2015 | 783 | 0.090 |
Why?
|
| Purpura | 1 | 2011 | 121 | 0.090 |
Why?
|
| Female | 16 | 2018 | 385090 | 0.090 |
Why?
|
| Arthralgia | 1 | 2014 | 457 | 0.090 |
Why?
|
| Measles | 1 | 2012 | 169 | 0.090 |
Why?
|
| Fever | 1 | 2017 | 1627 | 0.090 |
Why?
|
| Melanoma | 1 | 2008 | 5547 | 0.090 |
Why?
|
| Itraconazole | 1 | 2009 | 43 | 0.090 |
Why?
|
| Dermatitis | 1 | 2011 | 200 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2014 | 1859 | 0.080 |
Why?
|
| Antioxidants | 1 | 2017 | 1669 | 0.080 |
Why?
|
| Perception | 1 | 2015 | 1199 | 0.080 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 1101 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 8660 | 0.080 |
Why?
|
| Societies, Medical | 1 | 2020 | 3802 | 0.080 |
Why?
|
| Diagnostic Errors | 1 | 2016 | 1270 | 0.080 |
Why?
|
| Cryotherapy | 1 | 2009 | 161 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 20346 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2021 | 64017 | 0.080 |
Why?
|
| Intestine, Small | 1 | 2014 | 1244 | 0.080 |
Why?
|
| Nail Diseases | 1 | 2008 | 52 | 0.080 |
Why?
|
| Antimetabolites | 1 | 2008 | 125 | 0.080 |
Why?
|
| Platinum Compounds | 1 | 2008 | 97 | 0.080 |
Why?
|
| Lung | 2 | 2017 | 9990 | 0.080 |
Why?
|
| Blister | 1 | 2007 | 86 | 0.070 |
Why?
|
| Hair Diseases | 1 | 2008 | 75 | 0.070 |
Why?
|
| Tattooing | 1 | 2007 | 59 | 0.070 |
Why?
|
| Antineoplastic Agents | 2 | 2008 | 13678 | 0.070 |
Why?
|
| Benzenesulfonates | 1 | 2008 | 169 | 0.070 |
Why?
|
| Eosinophils | 1 | 2012 | 966 | 0.070 |
Why?
|
| Shoulder Joint | 1 | 2013 | 700 | 0.070 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2017 | 2846 | 0.070 |
Why?
|
| Curriculum | 1 | 2020 | 3633 | 0.070 |
Why?
|
| Pilot Projects | 1 | 2019 | 8413 | 0.070 |
Why?
|
| Middle Aged | 11 | 2017 | 216054 | 0.070 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2008 | 429 | 0.070 |
Why?
|
| Niacinamide | 1 | 2008 | 417 | 0.070 |
Why?
|
| Osteoarthritis | 1 | 2013 | 1049 | 0.070 |
Why?
|
| Aged | 5 | 2017 | 165629 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 58361 | 0.060 |
Why?
|
| Phenylurea Compounds | 1 | 2008 | 527 | 0.060 |
Why?
|
| Antifungal Agents | 1 | 2009 | 731 | 0.060 |
Why?
|
| Taxoids | 1 | 2008 | 671 | 0.060 |
Why?
|
| Antibodies, Viral | 1 | 2016 | 3194 | 0.060 |
Why?
|
| China | 1 | 2009 | 2306 | 0.060 |
Why?
|
| Doxycycline | 1 | 2004 | 329 | 0.050 |
Why?
|
| Benzamides | 1 | 2008 | 1382 | 0.050 |
Why?
|
| New York City | 1 | 2004 | 719 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 1812 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 3871 | 0.050 |
Why?
|
| Pyrroles | 1 | 2008 | 1145 | 0.050 |
Why?
|
| Quinazolines | 1 | 2008 | 1355 | 0.050 |
Why?
|
| Pandemics | 1 | 2021 | 8607 | 0.050 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2016 | 2446 | 0.050 |
Why?
|
| United States | 3 | 2022 | 70772 | 0.050 |
Why?
|
| Cancer Vaccines | 1 | 2008 | 1041 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 9305 | 0.050 |
Why?
|
| Cognition | 1 | 2017 | 6844 | 0.040 |
Why?
|
| Skin Pigmentation | 1 | 2022 | 290 | 0.040 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 5076 | 0.040 |
Why?
|
| Indoles | 1 | 2008 | 1839 | 0.040 |
Why?
|
| Faculty | 1 | 2022 | 388 | 0.040 |
Why?
|
| South Africa | 4 | 1996 | 1740 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2008 | 2450 | 0.040 |
Why?
|
| Autoantibodies | 2 | 1996 | 2068 | 0.040 |
Why?
|
| Piperazines | 1 | 2008 | 2502 | 0.040 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 1996 | 61 | 0.030 |
Why?
|
| Pyridines | 1 | 2008 | 2841 | 0.030 |
Why?
|
| Erythromycin | 1 | 1996 | 120 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2008 | 2987 | 0.030 |
Why?
|
| Schools, Medical | 1 | 2022 | 882 | 0.030 |
Why?
|
| Anti-Retroviral Agents | 1 | 2005 | 1727 | 0.030 |
Why?
|
| Anticonvulsants | 1 | 2005 | 1921 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 2287 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 25454 | 0.030 |
Why?
|
| Antibodies, Antinuclear | 1 | 1996 | 330 | 0.030 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2005 | 1622 | 0.030 |
Why?
|
| Quality of Life | 1 | 2015 | 13044 | 0.030 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 1996 | 2112 | 0.030 |
Why?
|
| Ribonucleoproteins | 1 | 1996 | 378 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 4420 | 0.030 |
Why?
|
| Community-Acquired Infections | 1 | 1996 | 465 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 5584 | 0.020 |
Why?
|
| Autoantigens | 1 | 1996 | 901 | 0.020 |
Why?
|
| Young Adult | 1 | 2016 | 57267 | 0.020 |
Why?
|
| Jews | 1 | 2011 | 387 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2005 | 4738 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2008 | 23512 | 0.020 |
Why?
|
| Pneumonia | 1 | 1996 | 2154 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1996 | 4575 | 0.010 |
Why?
|
| Lasers | 1 | 2007 | 961 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1996 | 7269 | 0.010 |
Why?
|
| HIV Infections | 1 | 2003 | 16882 | 0.010 |
Why?
|
| Counterimmunoelectrophoresis | 1 | 1996 | 15 | 0.010 |
Why?
|
| IgG Deficiency | 1 | 1996 | 28 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 15657 | 0.010 |
Why?
|
| Raynaud Disease | 1 | 1996 | 78 | 0.010 |
Why?
|
| Vasculitis | 1 | 1996 | 520 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1996 | 1407 | 0.010 |
Why?
|
| Acute Disease | 1 | 1996 | 7221 | 0.000 |
Why?
|
| Kidney Diseases | 1 | 1996 | 2136 | 0.000 |
Why?
|
| Adolescent | 3 | 1996 | 86713 | 0.000 |
Why?
|
| Psychotic Disorders | 1 | 1996 | 3102 | 0.000 |
Why?
|
| Prevalence | 1 | 1996 | 15404 | 0.000 |
Why?
|
| Retrospective Studies | 2 | 1996 | 78758 | 0.000 |
Why?
|
| Prognosis | 1 | 1996 | 29264 | 0.000 |
Why?
|
| Prospective Studies | 1 | 1996 | 53863 | 0.000 |
Why?
|